secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lexeo Therapeutics, Inc. (LXEO)
CIK:        0001907108
Form:       8-K
Filed at:   2025-10-07T23:59:59+00:00
Accession:  0001193125-25-232514
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lexeo gets FDA feedback for LX2006 accelerated approval; interim data show LVMI reduction, mFARS improvement
--------------------------------------------------------------------------------

- FDA open to pooling ongoing Phase 1/2 data with pivotal study to support BLA for accelerated approval.
- Abnormal-LVMI patients (n=6): 18% mean reduction at 6 months, 23% at 12 months, exceeding 10% FDA threshold.
- All participants (n=16) >6-mo follow-up: 2.0-point mean mFARS improvement; 11 of 16 improved or stabilized.
- LX2006 generally well tolerated; no Grade 3+ SAEs; no discontinuations; one Grade 2 asymptomatic myocarditis.
- Lexeo plans to initiate LX2006 pivotal study as soon as possible in first half of 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1907108/000119312525232514/0001193125-25-232514-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1907108/000119312525232514/lxeo-20251007.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-232514

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer